Lupin has achieved an impressive S&P Global ESG Score of 91 for 2025, significantly exceeding the pharmaceutical industry average of 28. This accomplishment positions Lupin among an exclusive group of companies worldwide to surpass the 90-point mark. This substantial improvement from a score of 17 in 2021 highlights Lupin’s commitment to sustainable growth and establishes it as a leader in the pharmaceutical sector.
Exceptional ESG Performance
Lupin announced its achievement of an S&P Global ESG Score of 91, marking a significant milestone in its sustainability journey. This score, attained for 2025, positions Lupin well above the industry average and recognizes its leadership in environmental, social, and governance practices.
Rapid Sustainability Improvement
The company has demonstrated remarkable progress, increasing its ESG score from 17 in 2021 to 91 in 2025. This improvement underscores Lupin’s dedication to integrating sustainability into its core business strategies and operations. The company’s focus on sustainable growth is setting new benchmarks in the pharmaceutical industry.
Commitment to Sustainability
According to Ramesh Swaminathan, Executive Director, Global CFO, and Head of IT and API Plus SBU, achieving a score above 90 in the S&P Global ESG ratings highlights the company’s unwavering commitment to sustainability. He also stated that Lupin is not only leading the pharmaceutical industry but also redefining and setting new standards for responsible growth by ensuring healthcare solutions that generate lasting value for patients, communities, and stakeholders worldwide.
Progress Across ESG Pillars
Lupin has made considerable progress across all three ESG pillars: Environmental, Social, and Governance. Key achievements include increased use of renewable energy, reduction of carbon emissions, water-positive operations, prioritizing employee well-being, promoting diversity and inclusion, and enhancing transparency and ethical business practices.
Source: BSE
